Lung Cancer Diagnostics Market Outlook 2031:
The global lung cancer diagnostics market size was valued at USD 14.10 Billion in 2022 and is projected to reach USD 26.58 Billion by 2031, expanding at a CAGR of 7.3% during the forecast period 2023 - 2031. The growth of the market is attributed to the increasing prevalence of cancer as well as development of innovative diagnostic kits and treatment methods.
Lung cancer diagnosis refers to a screening procedure for detecting the cancer formation near and at the lungs, which is helpful for the treatment of the disease. Some of the key techniques for lung cancer treatment including imaging, cytology testing, biopsy, and tumor screening. Market expansion of lung cancer diagnostics is aided by rapid introduction of technological advancements in the field of tumor diagnosis.
The need for more effective diagnostic systems arises from the fact that only 15% of lung cancer cases are diagnosed, while the remaining undiscovered cases progress to more aggressive forms. This result to lowering the 5-year survival rate to only 4% in patients diagnosed with late-stage lung cancer.
The frequency of smoking has increased the chance of cancer dramatically in the developing world, which is predicted to have an impact on lung cancer incidence rates in the coming years. The need for early cancer screening and diagnosis is directly related to market growth as the prevalence of cancer rises.
Lung Cancer Diagnostics Market Trends, Drivers, Restraints, and Opportunities
- Increasing public awareness regarding the benefits regarding early diagnosis due to rising occurrence of cancer among a large number of population globally is expected to fuel the market growth in the coming years.
- Raising funding for R&D activities from private and government bodies to develop better tumour diagnostic tools is anticipated to propel the market growth during the forecast period.
- Introduction of innovative technology and improvement of treatment techniques that improve accuracy in result are estimated to drive the market growth during the forecast period.
- High cost of the diagnosis and treatment of lung cancer and long treatment duration are key restraining factors projected to hamper the market growth.
Scope of the Lung Cancer Diagnostics Market Report
The report on the global lung cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Lung Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Types (Small Cell Lung Cancer and Non-small Cell Lung Cancer) and Tests (Imaging Test, Biopsy, Sputum Cytology, Molecular Test, and Others)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Roche Diagnostics; bioMérieu; Qiagen N.V.; Agilent Technologies; Thermo Fisher Scientific; AstraZeneca plc; Illumina Inc.; Janssen Pharmaceuticals, Inc.; and Sanofi S.A.
Lung Cancer Diagnostics Market Segment Insights
Non-small cell lung cancer segment is projected to account for a key market share
Based on types, the lung cancer diagnostics market is bifurcated into small cell lung cancer and non-small cell lung cancer. The non-small cell lung cancer segment is expected to account for a key share of the market during the forecast period owing to rising case of large tumor size. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cancer cases.
Large cell carcinoma, adenocarcinoma, squamous cell carcinoma, and other are less common kinds of NSCLC and are among the different subtypes of NSCLC. Meanwhile, the small cell lung cancer (SCLC) segment is anticipated to exhibit a high CAGR during the forecast period as the disease type spreads swiftly throughout the body easily.
The small cell lung tumors segment accounted for just around 10% of the global cancers diagnosis. SCLC is divided into two types: small-cell lung carcinoma and mixed small-cell lung cancer.
Molecular test segment is expected to grow at a rapid pace
On the basis of tests, the market is divided into imaging test, biopsy, sputum cytology, molecular test, and others. The molecular test segment is expected to expand at a rapid pace during the forecast period owing to new diagnostic test applications that have emerged as a result of improvements and innovations in molecular diagnostic technology.
The imaging tests segment, on the other hand, held a large market share in 2020 and is anticipated to grow significantly in the coming years owing to the widespread use of various imaging techniques such as MRI, CT scan, and X-ray as primary cancer screening tools.
Imaging studies are useful throughout the treatment period and act as an initial screening tool for lung cancer diagnosis. Lung cancer molecular tests allow for more tailored treatment. Specific proteins, genes, and other tumor-specific components known as mutations, including as EGFR, BRAF, ALK, ROS1, HER2, and RET, are identified with these assays.
Asia Pacific is anticipated to dominate the market
On the basis of regions, the global lung cancer diagnostics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the forecast period owing to the high market penetration rates of technologically advanced goods, increased patient awareness, and rising smoking prevalence levels in the region.
However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to rising penetration of advanced lung cancer diagnostic tools coupled with the rising awareness about the diseases symptoms.
The global lung cancer diagnostics market has been segmented on the basis of
- Small Cell Lung Cancer
- Non-small Cell Lung Cancer
- Imaging Test
- Sputum Cytology
- Molecular Test
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
Key players competing in the global lung cancer diagnostics market are Roche Diagnostics; bioMérieu; Qiagen N.V.; Agilent Technologies; Thermo Fisher Scientific; AstraZeneca plc; Illumina Inc.; Janssen Pharmaceuticals, Inc.; and Sanofi S.A.
These market participants are implementing a primary strategy of mergers and acquisitions with the goal of covering large distribution territories and developing unique products. For example, as part of the personalised medicine strategy, Illumina worked with pharma giants Janssen Pharmaceuticals Inc., AstraZeneca plc, and Sanofi S.A. to develop gene sequencing tools for the detection of lung cancer.
Furthermore, increasing research and development efforts to improve existing cancer detection tools is predicted to be a game-changing decision for end-users including hospitals and clinical laboratories.